Since this guideline was updated [8], there have been significant advancements in the field of diabetes and T2DM management, such as new and effective medicines including glucagon-like peptide-1 (GLP-1) receptor agonists as well as its alternatives; individualised care regimes tailored to the patient’s health status; prediction models; and recommendations to change current therapeutic practices made by the American College of Physicians [16,29,30,31,32,33], therefore resulting in potential inadequacies and inconsistencies in the guideline. The gene discussed is GCG; the disease is diabetes mellitus.